Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Real-world DFS as a predictor of OS in resected early-stage non-small cell lung cancer

Howard West, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, provides an overview of a retrospective, observational investigation into the association between real-world disease-free survival (DFS) and overall-survival (OS) in early stage non-small cell lung cancer (NSCLC). Additionally, the clinical and economic burden associated with recurrence among patients with resected early stage NSCLC was estimated. A positive correlation was found between real-world DFS and OS, and recurrence following resection was significantly associated with a shorter OS among patients with early-stage NSCLC. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Transcript (edited for clarity)

We looked at real-world data that assessed the association between recurrence-free survival and subsequent overall-survival. This is something that we have essentially assumed and with good reason, that if you have a relapse, you are likely to have a shorter survival, but these are data to speak to that. We also saw in really delving into the data that there are patients who have a risk of dying well beyond four and five years, times when you might think that if you’re still alive, you are completely in the clear...

We looked at real-world data that assessed the association between recurrence-free survival and subsequent overall-survival. This is something that we have essentially assumed and with good reason, that if you have a relapse, you are likely to have a shorter survival, but these are data to speak to that. We also saw in really delving into the data that there are patients who have a risk of dying well beyond four and five years, times when you might think that if you’re still alive, you are completely in the clear. Now in truth, a lot of the risk of dying beyond four or five years after surgery is from competing comorbidities, advancing age. This is a population that from the time of diagnosis at 70 or 72 or something you’re talking about now patients getting well into their 70s, but just that there is an ongoing drop off in survival. It is associated with a higher risk as if you have a relapse, but really that patients remain at risk of dying for many years after that.

Read more...